en · de · es · fr · pt
sr9009-notes.peptides7250.com › Wiki › Background And Mechanism Of Sr9009 — Research Overview

Background And Mechanism Of Sr9009 — Research Overview

By Editorial Desk · published 2025-11-26 · last reviewed 2026-01-06 · Wiki

If you have been reading about NR1D1 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Updated 2026-01-06. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Mechanism of SR9009

SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.

SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.

Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.

Analytical and Handling Considerations

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall-molecule ligand; not a hormone or peptide
Molecular formulaC20H24ClN3O4SReported for the free base
CAS Registry Number1379686-30-2Unique chemical identifier
Common synonymsSR9009; stenabolicStenabolic is informal and not an official name
Reported targetsREV-ERBα and REV-ERBβNuclear receptors linked to circadian and metabolic regulation

Analytical Detection and Laboratory Handling

Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.

In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.

Related pages on this site

SR9009 Background and Receptor Mechanism

SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.

Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.

Background and Receptor Mechanism

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.

SR9009 Handling and Quality Control

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.

Notes from published material

=== Fluorohistidine tags === A polyfluorohistidine tag has been reported for use in in vitro translation systems. In this system, an expanded genetic code is used in which histidine is replaced by 4-fluorohistidine. The fluorinated analog is incorporated into peptides via the relaxed substrate specificity of histidine-tRNA ligase and lowers the overall pKa of the tag. This allows for the selective enrichment of polyfluorohistidine tagged peptides in the presence of complex mixtures of traditional polyhistidine tags by altering the pH of the wash buffers.

Dill (Anethum graveolens) is an annual herb in the celery family Apiaceae. Native to North Africa and West Asia, dill is grown widely in Eurasia, where its leaves and seeds are used as a herb or spice for flavouring food.

=== Pros and cons === Osmotic release systems have a number of major advantages over other controlled-release mechanisms. They are significantly less affected by factors such as pH, food intake, GI motility, and differing intestinal environments. Using an osmotic pump to deliver drugs has additional inherent advantages regarding control over drug delivery rates. This allows for much more precise drug delivery over an extended period of time, which results in much more predictable pharmacokinetics. However, osmotic release systems are relatively complicated, somewhat difficult to manufacture, and may cause irritation or even blockage of the GI tract due to prolonged release of irritating drugs from the non-deformable tablet.

Although Mr Galloway, Mr Halford and Mr Al-Mukhtar have confirmed that they were unaware of the source of Mr Zureikat's donations, the Commission has concluded that the charity trustees should have made further enquiries when accepting such large single and cumulative donations to satisfy themselves as to their origin and legitimacy. The Commission's conclusion is that the charity trustees did not properly discharge their duty of care as trustees to the Appeal in respect of these donations ... The Commission is also concerned, having considered the totality of the evidence before it, that Mr Galloway may also have known of the connection between the Appeal and the Programme. Galloway, in response, stated: "I've always disputed the Commission's retrospective view that a campaign to win a change in national and international policy – a political campaign – was, in fact, a charity".

Sources: en.wikipedia.org

Background from the literature

Highly caffeinated, often highly sweetened, energy drinks are common on the beverage market worldwide. Consumer demand has helped generate a new generation of energy drink brands containing similar amounts of caffeine, calories, and sugar. Various ingredients found in energy drinks may include taurine, caffeine, B vitamins, guarana, ginseng, ginkgo biloba, L-carnitine, sugars, yerba maté, and creatine. Although these ingredients have been approved by the United States Food and Drug Administration, health experts recommend that consumers understand contents shown on the product labels, as these ingredients are not included to improve health. In some functional beverages, particularly energy drinks, the caffeine content can range from 50 to 200 milligrams per serving. According to Health Canada, beverage products with variable levels of caffeine may not be safe for children.

During the night of 21 February, local sources in Afghanistan reported airstrikes in parts of Nangarhar, Paktika, and Khost provinces. In Nangarhar, strikes were reported in the Bihsud and Khogyani districts, while in Paktika, strikes were reported in the Barmal and Urgun districts. Local sources reported that the airstrikes in Nangarhar's Bihsud district struck a civilian home, trapping 23 people beneath the rubble. Pakistan's Ministry of Information and Broadcasting (MolB) stated that the Pakistani military conducted "intelligence-based selective targeting" of seven terrorist camps and hideouts along the Afghanistan-Pakistan border region. The Taliban claimed that the targets included civilian homes and a religious seminary. In a late-night press release, Pakistani officials confirmed that the Pakistan Air Force (PAF), under the command of Air Chief Marshal Zaheer Ahmad Babar, had carried out airstrikes in Afghanistan. Officials said the strikes were selective and intelligence-based, and targeted seven militant camps and hideouts linked to the Tehrik-i-Taliban Pakistan (TTP) and the Islamic State – Khorasan Province (ISIS–K) near the Afghanistan-Pakistan border. Pakistani officials added that the strikes were conducted as retaliation for recent terror attacks in Islamabad, Bajaur, and Bannu.

== Further reading == Ahnström, M. L.; Seyfert, M.; Hunt, M. C.; Johnson, D. E. (2006). "Dry aging of beef in a bag highly permeable to water vapor". Meat Science. 73 (4): 674–679. doi:10.1016/j.meatsci.2006.03.006. PMID 22062568. DeGeer, S. L.; Hunt, M. C.; Bratcher, C. L.; Crozier-Dodson, B. A.; Johnson, D. E.; Stika, J. F. (2009). "Effects of dry aging of bone-in and boneless strip loins using two aging processes for two aging times". Meat Science. 83 (4): 768–774. doi:10.1016/j.meatsci.2009.08.017. PMID 20416624.

== Treatment == There is no distinct treatment option that can undo the effects and damage from rhabdomyolysis because it is a type of necrosis, where the tissue and body cells die prematurely. However, the rate of the pathology that can lead to more complications can be decreased by acting early and consistently. Overall treatment depends on preventing kidney failure (renal failure) which is done by rehydrating the patient. It also depends on making urine have a more basic pH (alkalinization of urine).

The unusual stability of the helium-4 nucleus is also important cosmologically: it explains the fact that in the first few minutes after the Big Bang, as the "soup" of free protons and neutrons which had initially been created in about 6:1 ratio cooled to the point that nuclear binding was possible, almost all first compound atomic nuclei to form were helium-4 nuclei. Owing to the relatively tight binding of helium-4 nuclei, its production consumed nearly all of the free neutrons in a few minutes, before they could beta-decay, and thus few neutrons were available to form heavier atoms such as lithium, beryllium, or boron. Helium-4 nuclear binding per nucleon is stronger than in any of these elements (see nucleogenesis and binding energy) and thus, once helium had been formed, no energetic drive was available to make elements 3, 4 and 5. It is barely energetically favorable for helium to fuse into the next element with a lower energy per nucleon, carbon. However, due to the short lifetime of the intermediate beryllium-8, this process requires three helium nuclei striking each other nearly simultaneously (see triple-alpha process). There was thus no time for significant carbon to be formed in the few minutes after the Big Bang, before the early expanding universe cooled to the temperature and pressure point where helium fusion to carbon was no longer possible. This left the early universe with a very similar ratio of hydrogen/helium as is observed today (3 parts hydrogen to 1 part helium-4 by mass), with nearly all the neutrons in the universe trapped in helium-4.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.

Is SR9009 approved for human use?

No. It has no approved medical indication, and human safety and efficacy data are limited. It appears in research chemical markets and is banned by some sports authorities.

How does SR9009 differ from natural REV-ERB ligands?

Natural ligands include heme and certain metabolites; SR9009 is a synthetic small molecule with higher potency and selectivity in some assays. Its effects depend on cell type and timing. It is not a naturally occurring compound.

How is SR9009 detected in laboratory samples?

Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.

Network